ArticleProbiotics and antimicrobial proteins2026
Probiotic Kefir Improves Renal Disorders in Ovariectomized Female SHR with High Fructose Intake-Induced Metabolic Syndrome.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Renal Function of the Wild Rodent Cerradomys goytaca Reveals Adaptations in the Mechanisms of Urinary Concentration and Solute Excretion.Journal of experimental zoology. Part A, Ecological and integrative physiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Women in postmenopausal period may present several comorbidities linked to metabolic syndrome (MetS). Our hypothesis is that kefir may prevent the deleterious effects in renal function in an experimental model of metabolic syndrome (MetS) and ovarian hormone deficiency. Young female spontaneously hypertensive rats (SHR) were divided into four groups: ovariectomized (OVX) control, OVX fructose, OVX kefir, and OVX kefir + fructose. They received kefir (5% w/v) via gavage for 8 weeks, while fructose (10% w/v) was available ad libitum. In ponderal parameters and glucose metabolism, we observe that fructose-overloaded groups (OF and OKF) showed increased weight, visceral fat, and fasting blood glucose. However, OKF partially reduced glycemic peak in the glucose tolerance test. Moreover, the standard method for the measurement of renal function showed that OF and OKF groups had a reduction in glomerular filtration rate, and surprisingly OKF exhibited increased renal flow (RBF and RPF) and decreased resistance (RVR). These might be associated with the findings in oxidative stress and nitric oxide (NO) bioavailability, in which kefir in the OKF group was capable of increasing total nitrogen oxides (NOx), attenuate the generation of hydrogen peroxide (DCF) and peroxynitrite (HPF), and also decreased the elevated microalbuminuria promoted by fructose even though the systemic blood pressure between the groups did not differ. Taking together our results, in the present study, kefir showed favorable effects in the model of metabolic syndrome and ovarian hormone deficiency (OKF), potentially protecting the kidney from the deleterious effects of fructose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.